» Articles » PMID: 31671481

The Win Ratio: Impact of Censoring and Follow-up Time and Use with Nonproportional Hazards

Overview
Journal Pharm Stat
Publisher Wiley
Date 2019 Nov 1
PMID 31671481
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The win ratio has been studied methodologically and applied in data analysis and in designing clinical trials. Researchers have pointed out that the results depend on follow-up time and censoring time, which are sometimes used interchangeably. In this article, we distinguish between follow-up time and censoring time, show theoretically the impact of censoring on the win ratio, and illustrate the impact of follow-up time. We then point out that, if the treatment has long-term benefit from a more important but less frequent endpoint (eg, death), the win ratio can show that benefit by following patients longer, avoiding masking by more frequent but less important outcomes, which occurs in conventional time-to-first-event analyses. For the situation of nonproportional hazards, we demonstrate that the win ratio can be a good alternative to methods such as landmark survival rate, restricted mean survival time, and weighted log-rank tests.

Citing Articles

The Win Ratio Approach in Bayesian Monitoring for Two-Arm Phase II Clinical Trial Designs With Multiple Time-To-Event Endpoints.

Huang X, Wang J, Ning J Stat Med. 2024; 43(30):5922-5934.

PMID: 39582325 PMC: 11645213. DOI: 10.1002/sim.10282.


Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension.

Weatherald J, Fleming T, Wilkins M, Cascino T, Psotka M, Zamanian R Eur Respir J. 2024; 64(4).

PMID: 39209468 PMC: 11525337. DOI: 10.1183/13993003.01205-2024.


Defining estimand for the win ratio: Separate the true effect from censoring.

Mao L Clin Trials. 2024; 21(5):584-594.

PMID: 39076157 PMC: 11502278. DOI: 10.1177/17407745241259356.


Win Statistics in Pulmonary Arterial Hypertension Clinical Trials.

Weatherald J, Moutchia J, Al-Naamani N, McClelland R, Ventetuolo C, Palevsky H Am J Respir Crit Care Med. 2023; 208(11):1231-1234.

PMID: 37734029 PMC: 10868347. DOI: 10.1164/rccm.202305-0800LE.


Power and Sample Size Calculations for the Restricted Mean Time Analysis of Prioritized Composite Endpoints.

Mao L Stat Biopharm Res. 2023; 15(3):540-548.

PMID: 37663164 PMC: 10473860. DOI: 10.1080/19466315.2022.2110936.